Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Although immune mechanisms can suppress tumour growth, tumours establish potent, overlapping mechanisms that mediate immune evasion. Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms. Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system. Thus, the counter-activation of tolerance mechanisms at the site of tumour hypoxia would be a crucial condition for maintaining the immunological escape of tumours. However, a direct link between tumour hypoxia and tolerance through the recruitment of regulatory cells has not been established. We proposed that tumour hypoxia induces the expression of chemotactic factors that promote tolerance. Here we show that tumour hypoxia promotes the recruitment of regulatory T (T(reg)) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis. Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia, through HIF-1α, drives the conversion of MDSCs into antigen-nonspecific suppressors of T cell function and promotes the differentiation of MDSCs into immune-suppressive TAMs, further potentiating the immune-suppressive network [80].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [80]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [181]
In the citing paper
“tumours secrete soluble factors, such as C-C-motif chemokine ligand 2 (CCL2), CCL28, C-X-C-motif chemokine ligand 8 (CXCL8), CXCL12, ANG2, VEGF, PlGF, and adenosine, all of which promote the recruitment of immunosuppressive cells7,17–20 (FIG. 2)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [17]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationSummaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Cited by
Items 701–800 of 1,002
Liu, L., Xie, F., Chang, K., Li, M., Meng, Y., Wang, X., Li, H., Li, D., & Yu, J. (2014) · Europe PMC (PubMed Central) · Cited by 35
Goswami, K. K., Sarkar, M., Ghosh, S., Saha, A., Ghosh, T., Guha, I., Barik, S., Banerjee, S., Roy, S., Bose, A., et al. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.10.008 · Cited by 31
Basal, L. A., Yan, Y., Shen, Y., Haacke, E. M., Mehrmohammadi, M., & Allen, M. J. (2017) · ACS Omega · doi:10.1021/acsomega.6b00514 · Cited by 28
CCL28 promotes locomotor recovery after spinal cord injury via recruiting regulatory T cells
Wang, P., Qi, X., Xu, G., Liu, J., Guo, J., Li, X., Ma, X., & Sun, H. (2019) · Aging · doi:10.18632/aging.102239 · Cited by 30
“Coincidentally, two previous studies have also shown that CCL28 facilitates the trafficking and extravasation of Treg cells through binding to CCR10 [21, 22], together with our findings, suggesting that CCL28-CCR10 axis might be a general paradigm in which CCL28 recruits Treg cells.”
BackgroundResultSun, C., Zhang, Y., Tang, C.-L., Wang, S., Piao, H., Yu, T., Zhu, R., Du, M., & Li, D. (2013) · Molecular Human Reproduction · doi:10.1093/molehr/gat038 · Cited by 29
“Tumor hypoxia promotes the recruitment of regulatory T cells through induction of CCL28 expression, which in turn promotes tumor tolerance and angiogenesis (Facciabene et al., 2011).”
BackgroundYang, L., Zhang, D., Lu, D., Shi, Y., Jia, G., Wang, S., Zhang, K., Zhao, K., & Luan, Y. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.152032 · Cited by 29
Strategies to Interfere with Tumor Metabolism through the Interplay of Innate and Adaptive Immunity
Mora, J., Mertens, C., Meier, J. K., Fuhrmann, D. C., Brüne, B., & Jung, M. (2019) · Cells · doi:10.3390/cells8050445 · Cited by 27
“Moreover, hypoxia induces the recruitment of Tregs to the tumor microenvironment through CCL28 expression on tumor cells [124,125] and the expression of Foxp3 [126], thereby promoting intratumoral immune suppression.”
BackgroundCCL28‐induced CCR10/eNOS interaction in angiogenesis and skin wound healing
Chen, Z., Haus, J. M., Chen, L., Wu, S., Urao, N., Koh, T. J., & Minshall, R. D. (2020) · The FASEB Journal · doi:10.1096/fj.201902060r · Cited by 28
Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield
Jo, Y., Ali, L. A., Shim, J. A., Lee, B. H., & Hong, C. (2020) · Cancers · doi:10.3390/cancers12082087 · Cited by 30
“TM E Immune suppressor cells [41] [42] [44]”
Hui, Z., Zhang, J., Zheng, Y., Yang, L., Yu, W., An, Y., Wei, F., & Ren, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.619932 · Cited by 29
“an HIF-1α-dependent manner, and CCL28 recruits CCR10expressing effector Tregs into the neoplasm to promote tumor growth (22, 23, 51).”
BackgroundInfluentialRecent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
Ho, R. L. Y., & Ho, I. A. W. (2021) · Cancers · doi:10.3390/cancers13153686 · Cited by 34
“In malignant gliomas, tumor-associated microglia/macrophages (TAMs), the main component of the glioma microenvironment, crosstalk with Treg cells to release proangiogenic and immune-suppressive VEGF as part of shaping an antitumor microenvironment [17].”
BackgroundIntegration of local and systemic immunity in ovarian cancer: Implications for immunotherapy
Rajtak, A., Ostrowska-Leśko, M., Żak, K., Tarkowski, R., Kotarski, J., & Okła, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018256 · Cited by 32
“CCL28 High CCL28 levels associated with recruitment of Tregs cells and poor disease outcome (79)”
BackgroundChemokine Receptors in Epithelial Ovarian Cancer
Muralidhar, G. G., & Barbolina, M. V. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms15010361 · Cited by 28
“Adoptive transfer of anti-tumor T-cells has been proposed as a mechanism to suppress endogenous anti-tumor immunity for better treatments of this deadly disease.”
BackgroundInfluentialEmerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors
Askoxylakis, V., Arvanitis, C., Wong, C. S. F., Ferraro, G. B., & Jain, R. K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.011 · Cited by 28
Elhusseiny, K. M., Abd‐Elhay, F. A., Kamel, M. G., Hassan, H. H. A. E. H., Eltanany, H. H., Hieu, T. H., Tieu, T. M., Low, S. K., Hou, V., Dibas, M., et al. (2019) · Head & Neck · doi:10.1002/hed.25742 · Cited by 29
Functional CT Contrast Nanoagents for the Tumor Microenvironment
Meng, X., Wu, Y., & Bu, W. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000912 · Cited by 27
Sarkar, I., Basak, D., Ghosh, P., Gautam, A., Bhoumik, A., Singh, P., Kar, A., Mahanti, S., Chowdhury, S., Chakraborty, L., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt2117 · Cited by 27
Neoangiogenesis in Melanoma: An Issue in Biology and Systemic Treatment
Quaresmini, D., & Guida, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584903 · Cited by 30
“VEGF-R1 and -2 are expressed on DCs, which can promote angiogenesis (44).”
BackgroundInfluentialEffects of exercise and anti-PD-1 on the tumour microenvironment
Buss, L. A., Williams, T., Hock, B. D., Ang, A. D., Robinson, B. A., Currie, M. J., & Dachs, G. U. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.08.005 · Cited by 30
Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment
Wei, J., Hu, M., & Du, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845923 · Cited by 34
“PD-L1 is upregulated inMDSCs, andblockingPD-L1decreases IL-6 and IL-10 expression in MDSCs and abrogates the suppression toCD8Tcells under hypoxia conditions (54).”
BackgroundIGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer
Yi, X., Zheng, X. S., Xu, H., Li, J., Zhang, T., Ge, P., Liao, D., Li, H., Lyu, X., & Ai, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898493 · Cited by 27
“Although immune infiltration can increase via the interaction of IGFBP7 and CD93, hypoxia drives the preferential recruitment of Tregs, which express negative costimulatory molecules and lead to inadequate costimulation for T-cell activation (58, 59).”
BackgroundAria, H., Rezaei, M., Nazem, S., Daraei, A., Nikfar, G., Mansoori, B., Bahmanyar, M., Tavassoli, A., Vakil, M. K., & Mansoori, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947885 · Cited by 28
Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
Liu, J., Tao, H., Yuan, T., Li, J., Li, J., Liang, H., Huang, Z., & Zhang, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992611 · Cited by 32
“Frontiers in Immunology 06 indirectly results in the accumulation of Tregs in the tumor microenvironment (136).”
BackgroundEmerging evidence of immunotherapy for colorectal cancer
Miyamoto, Y., Ogawa, K., Ohuchi, M., Tokunaga, R., & Baba, H. (2022) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12633 · Cited by 29
Zhang, L., Tang, L., Yu, C., Xiao, H., & Liu, C. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202310450 · Cited by 33
Self-citationImmune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit
Kostecki, K. L., Iida, M., Crossman, B. E., Salgia, R., Harari, P. M., Bruce, J. Y., & Wheeler, D. L. (2024) · Cancers · doi:10.3390/cancers16020312 · Cited by 30
“HNC cells recruit T reg s through several chemokines and their associated receptors, including CCL2/CCR4, CCL28/CCR10, and CXCL12/C-X-C motif chemokine receptor (CXCR)4 [330–333].”
BackgroundPredicting risk of recurrence after resection of stage I intrahepatic cholangiocarcinoma
Kawashima, J., Sahara, K., Shen, F., Guglielmi, A., Aldrighetti, L. A., Weiss, M. J., Bauer, T. W., Alexandrescu, S. T., Poultsides, G. A., Maithel, S. K., et al. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2023.10.002 · Cited by 29
Nasti, T. H., Bullard, D. C., & Yusuf, N. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.02.025 · Cited by 28
Pathania, A. S., Wani, Z. A., Guru, S. K., Kumar, S. G., Bhushan, S., Körkaya, H., Seals, D. F., Kumar, A., Mondhe, D. M., Ahmed, Z., et al. (2015) · Molecular Cancer · doi:10.1186/1476-4598-14-6 · Cited by 28
Bagaria, S. P., Gatalica, Z., Maney, T., Serie, D., Parasramka, M. A., Attia, S., Krishna, M., & Joseph, R. W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00071 · Cited by 26
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors
Zhang, G., Bai, M., Du, H., Yuan, Y., Wang, Y., Fan, W., Zhu, H., Wu, D., He, P., & Xue, B. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s519616 · Cited by 29
“170,173 The accumulation of metabolites and hazardous substances inhibits T cell activity also contributes to T cell exhaustion as well.”
Convergences and Divergences of Thymus- and Peripherally Derived Regulatory T Cells in Cancer
Burocchi, A., Colombo, M. P., & Piconese, S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00247 · Cited by 27
Aberrant frequency of TNFR2+ Treg and related cytokines in patients with CIN and cervical cancer
Zhang, T., Jiao, J., Jiao, X., Zhao, L., Tian, X., Zhang, Q., Ma, D., & Cui, B. (2017) · Oncotarget · doi:10.18632/oncotarget.23581 · Cited by 25
“Previous studies have shown that chemokines secreted by tumor cells in situ, such as CCmotif ligand 22 and CC-motif ligand 28, play an important role in recruiting Tregs into tumor tissues [7, 28, 29].”
ResultRegulatory T Cells in Gynecologic Cancer
Ou, Y., Cannon, M. J., & Nakagawa, M. (2018) · MOJ Immunology · doi:10.15406/moji.2018.06.00189 · Cited by 27
Feng, Y., Dai, Y., Gong, Z., Cheng, J., Zhang, L., Sun, C., Zeng, X., Jia, Q., & Zhu, B. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s162729 · Cited by 25
“4,37 In our study, the potent impact of angiogenesis on the TME of gastric cancers was validated by machine learning, using RNA sequencing data in a large cohort of gastric cancers from the TCGA database.”
Self-citationRegulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions
Zeng, G., Jin, L., Ying, Q., Chen, H., Thembinkosi, M. C., Yang, C., Zhao, J., Ji, H., Lin, S., Peng, R., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s265828 · Cited by 28
Ganguly, K., Shah, A., Atri, P., Rauth, S., Ponnusamy, M. P., Kumar, S., & Batra, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.022 · Cited by 26
Zhang, S., Li, P., Li, J., Gao, J., Qi, Q., Dong, G., Liu, X., Jiao, Q., Wang, Y., Du, L., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02313-y · Cited by 29
Hypoxia in the intestine or solid tumors: A beneficial or deleterious alarm signal?
Shehade, H., Oldenhove, G., & Moser, M. (2014) · European Journal of Immunology · doi:10.1002/eji.201444719 · Cited by 27
Impaired migration of IgA-secreting cells to colon adenocarcinomas
Muthuswamy, R. V., Sundström, P., Börjesson, L., Gustavsson, B. G., & Quiding‐Järbrink, M. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1410-1 · Cited by 25
“nocarcinomas due to hypoxia [41], while pleomorphic adenomas of the salivary glands and mammary tumors”
BackgroundMaghazachi, A. A., Sand, K. L., & Al‐Jaderi, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00437 · Cited by 25
Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer
Uldry, É., Faes, S., Demartines, N., & Dormond, O. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071401 · Cited by 29
“Hypoxia further fosters an immunosuppressive tumor microenvironment by recruiting T regulatory cells and polarizing tumor associated macrophages to an M2 phenotype [53,74].”
BackgroundRecent development in biodegradable nanovehicle delivery system-assisted immunotherapy
Wen, Z., Liu, F., Chen, Q., Xu, Y., Li, H., & Sun, S. (2019) · Biomaterials Science · doi:10.1039/c9bm00961b · Cited by 27
Wang, X., Dong, H.-S., Li, Q., Li, Y., & Hong, A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027471 · Cited by 25
“Preliminary work showed that tumor hypoxia promotes the recruitment of Tregs through induction of expression of the chemokine CCL28, which, in turn, promotes tumor tolerance and angiogenesis.(25) Another study suggested that CCR4 antagonists, an emergent class of Treg inhibitor, block recruitment of Tregs mediated by…”
BackgroundTranscriptional regulation of VEGFA expression in T-regulatory cells from breast cancer patients
Kajal, K., Bose, S., Panda, A. K., Chakraborty, D., Chakraborty, S., Pati, S., Sarkar, T., Dhar, S., Roy, D., Saha, S., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02808-0 · Cited by 26
Immunomodulation for glioblastoma
Reardon, D. A., Wen, P. Y., Wucherpfennig, K. W., & Sampson, J. H. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000451 · Cited by 26
Engineering Mechanical Microenvironment of Macrophage and Its Biomedical Applications
Li, J., Li, Y., Gao, B., Qin, C., He, Y., Xu, F., Yang, H., & Lin, M. (2018) · Nanomedicine · doi:10.2217/nnm-2017-0324 · Cited by 26
Tsukita, Y., Okazaki, T., Ebihara, S., Komatsu, R., Nihei, M., Kobayashi, M., Hirano, T., Sugiura, H., Tamada, T., Tanaka, N., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1543526 · Cited by 26
Dendritic cells in autoimmune disorders and cancer of the thyroid
Lewiñski, A., Śliwka, P. W., & Stasiołek, M. (2014) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.2014.0002 · Cited by 24
“An expansion of various regulatory cell populations such as DCs [72, 75, 76], Tregs [67, 74, 77, 78] or myeloid-derived suppressor cells [67, 79, 80] plays most probably a crucial role in this process.”
BackgroundXu, Y., Miller, C. P., Tykodi, S. S., Akilesh, S., & Warren, E. H. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1387198 · Cited by 31
Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy
Lian, H., Ma, S., Zhao, D., Zhao, W., Cui, Y., Hua, Y., & Zhang, Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122606 · Cited by 26
Cutibacterium acnes‐derived extracellular vesicles promote tumor growth in renal cell carcinoma
Jingushi, K., Kawashima, A., Tanikawa, S., Saito, T., Yamamoto, A., Uemura, T., Sassi, N., Ishizuya, Y., Yamamoto, Y., Kato, T., et al. (2024) · Cancer Science · doi:10.1111/cas.16202 · Cited by 23
Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy
Ryba-Stanisławowska, M. E. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00992-0 · Cited by 26
“They express chemokine receptors that enable their migration to cancerous lesions from various sites, including the thymus, lymph nodes, bone marrow, or peripheral blood [108, 110–118].”
T regulatory Cell-mediated Immunotherapy for Solid Organ Transplantation: A Clinical Perspective
Khan, M. A. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00050 · Cited by 25
Kinoshita, M., Kobayashi, S., Gotoh, K., Kubo, M., Hayashi, K., Iwagami, Y., Yamada, D., Akita, H., Noda, T., Asaoka, T., et al. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-06011-9 · Cited by 24
“It seems that cancer cells that have escaped from immune responses are carrying out proliferation, anti-apoptosis, and angiogenesis with further malignant trait acquisition [31, 32].”
BackgroundFang, L., Zhao, W., Ye, B., & Chen, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670313 · Cited by 25
“Moreover, through the expression and secretion of pro-angiogenic factors, some other myeloid cell subgroups might be also equipped with the ability to promote angiogenesis, including TAMs, Tregs, B cells, monocytes and neutrophils (31).”
BackgroundJonasch, E. W., Atkins, M. B., Chowdhury, S., & Mainwaring, P. N. (2022) · Cancers · doi:10.3390/cancers14030644 · Cited by 25
“Regulatory T cells themselves have been shown to be pro-angiogenic [33].”
BackgroundYoon, S.-H., Choi, S.-W., Nam, S. W., Lee, K. B., & Nam, J. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00167-2 · Cited by 25
Liu, J., Wang, X., Deng, Y., Yu, X., Wang, H., & Li, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.766248 · Cited by 27
Byrnes, J. R., Weeks, A. M., Shifrut, E., Carnevale, J. C., Kirkemo, L. L., Ashworth, A., Marson, A., & Wells, J. A. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100217 · Cited by 25
“Furthermore, hypoxia promotes recruitment of Tregs to the tumor (27) and CD8 cells have been observed to be excluded from areas of tumor hypoxia (28).”
BackgroundNanomodulators targeting tumor-resident immunosuppressive cells: Mechanisms and recent updates
Shen, X., Zhu, C., Wu, Q., Shi, J., Wu, W., Zhao, X., Sun, J., Li, H., & Gu, Z. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101641 · Cited by 22
Ling, T., Zhang, L., Peng, R., Yue, C., & Huang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1014063 · Cited by 25
“Angelo Castello 2020 (30) 23/12 77 (51-86) Prospective Before treatment Advanced Metastatic Nivolumab or pembrolizumab or nivolumab plus ipilimumab or atezolizumab 13.”
BackgroundInfluentialSelf-citationCavazzoni, A., Digiacomo, G., Volta, F., Alfieri, R. R., Giovannetti, E., Gnetti, L., Bellini, L., Galetti, M., Fumarola, C., Xu, G., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107438 · Cited by 24
Karlsson, C., Baudet, A., Miharada, N., Soneji, S., Gupta, R., Magnusson, M., Enver, T., Karlsson, G., & Larsson, J. T. (2013) · Blood · doi:10.1182/blood-2013-02-481192 · Cited by 22
Antitumor Efficacy of CC Motif Chemokine Ligand 19 in Colorectal Cancer
Lü, J., Zhao, J., Feng, H., Wang, P., Zhang, Z., Zong, Y., Ma, J., Zheng, M., & Lu, A. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3138-y · Cited by 22
Khan, M. A., Alanazi, F., Ahmed, H. A., Almohanna, F., Assiri, A. M., & Broering, D. C. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.11.011 · Cited by 22
Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses
Lee, S., Choi, S., Kim, S. Y., Yun, M., & Kim, H. (2017) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2017.17.e43 · Cited by 22
“Regarding the former, FDG uptake is upregulated in hypoxic conditions [17,40,41], and it is well-known that hypoxia modulates immune responses in the tumor microenvironment [36,42] and promotes proliferation of regulatory T cells [18,43].”
BackgroundNon-canonical PD-1 signaling in cancer and its potential implications in clinic
Zha, H., Jiang, Y., Wang, X., Shang, J., Wang, N., Yu, L., Zhao, W., Li, Z., Zhang, X., Zhang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001230 · Cited by 25
Waninger, J. J., Ma, V. T.-L., Journey, S. N., Skvarce, J., Chopra, Z., Tezel, A., Bryant, A. K., Mayo, C. S., Sun, Y., Sankar, K. N., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.0980 · Cited by 24
The Role of Post-Translational Modifications of Chemokines by CD26 in Cancer
Zutter, A. D., Damme, J. V., & Struyf, S. (2021) · Cancers · doi:10.3390/cancers13174247 · Cited by 23
“In ovarian cancer, CCL28 expression correlated with a poor prognosis [155].”
BackgroundXu, Q., & Shao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1487610 · Cited by 27
Cui, M., Zhou, M., Zhou, L., Zhou, G., & Liu, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189312 · Cited by 24
Lei, X., Zheng, B., Peng, Y., Zhang, G., Cheng, X., Li, W., He, J., Li, F., Ling, R., Fu, Z., et al. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.113325 · Cited by 21
Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment
Hameed, S., Bhattarai, P., & Dai, Z. (2018) · Science China Life Sciences · doi:10.1007/s11427-017-9256-1 · Cited by 21
Spatiotemporal T cell dynamics in a 3D bioprinted immunotherapy model
Morley, C. D., Flores, C., Drake, J., Moore, G. L., Mitchell, D. A., & Angelini, T. E. (2022) · Bioprinting · doi:10.1016/j.bprint.2022.e00231 · Cited by 24
“Similarly, we observe downregulation of CCL28 which has been identified as pro-tumoral in other cancers [25, 26].”
BackgroundCC Chemokine Ligand-2: A Promising Target for Overcoming Anticancer Drug Resistance
Shi, Z., Tu, J., Ying, Y., Diao, Y., Zhang, P., Liao, S., Xiong, Z., & Huang, S. (2022) · Cancers · doi:10.3390/cancers14174251 · Cited by 21
“An in-depth mechanistic study found that ETV5 not only upregulated VEGFA but also increased the expression of CCL2 [29].”
BackgroundInfluentialTumor immune microenvironment and systemic response in breast cancer
Kawaguchi, K., Maeshima, Y., & Toi, M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01782-0 · Cited by 22
Migratory Engineering of T Cells for Cancer Therapy
Michaelides, S., Obeck, H., Kechur, D., Endres, S., & Kobold, S. (2022) · Vaccines · doi:10.3390/vaccines10111845 · Cited by 21
“been identified out of literature [26, 28, 45-54] and apply to different entities.”
BackgroundMethodModulation of T cell function and survival by the tumor microenvironment
Mani, N. L., Andrews, D., & Obeng, R. C. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1191774 · Cited by 22
“In ovarian and hepatocellular tumors, hypoxia can drive the increased secretion of CCL28 that leads to increased recruitment of CCR10-expressing T regs into the TME (Facciabene et al., 2011; Ren et al., 2016).”
BackgroundTokumasu, M., Nishida, M., Zhao, W., Chao, R., Imano, N., Yamashita, N., Hida, K., Naito, H., & Udono, H. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404778121 · Cited by 24
Li, X., Wang, X., Hua, M., Yu, H.-H., Wei, S., Wang, A., & Zhou, J. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b00478 · Cited by 21
Harms, J. K., Lee, T. W., Wang, T., Lai, A., Kee, D., Chaplin, J. M., McIvor, N., Hunter, F. W., Macann, A., Wilson, W. R., et al. (2019) · Cells · doi:10.3390/cells8070717 · Cited by 22
“Hypoxia can also limit the activity of immunotherapy drugs by activating immune checkpoints [17], recruiting regulatory T cells [18], and suppressing T-cell function [19].”
BackgroundArmani, G., Pozzi, E., Pagani, A., Porta, C., Rizzo, M., Cicognini, D., Rovati, B., Moccia, F. D., Pedrazzoli, P., & Ferraris, E. (2021) · Microvascular Research · doi:10.1016/j.mvr.2021.104189 · Cited by 23
Improved Immunotherapy Efficacy by Vascular Modulation
Newport, E., Pedrosa, A., Njegić, A., Hodivala‐Dilke, K., & Muñoz‐Félix, J. M. (2021) · Cancers · doi:10.3390/cancers13205207 · Cited by 21
Filippi, L., Pini, A., Cammalleri, M., Bagnoli, P., & Monte, M. D. (2021) · Medicinal Research Reviews · doi:10.1002/med.21874 · Cited by 25
Mi, L., Yuan, J.-Y., Jiang, Y., Hu, Y., Lv, C., Xu, Y., Liu, M., Liu, T., Liu, X.-H., Huang, J., et al. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2486840 · Cited by 18
“…critical role in regulating migration of inflammatory cells and inflammation mediator release, thus being closely related to neurological diseases (Facciabene et al. 2011, li et al. 2016). cXcR4/sDF-1 axis has been proved to promote the proliferation of neural precursor cells and the migration of…”
Neophytou, C., Stylianopoulos, T., & Mpekris, F. (2025) · npj Biological Physics and Mechanics. · doi:10.1038/s44341-025-00017-3 · Cited by 20
“It also attracts immunosuppressive T-regulator cells (Tregs) by triggering the expression of the chemokine CCL28 35 and along with acidity 36 , affects differentiation and function of T-lymphocytes and myeloid cells 37 and induces TAMs to promote angiogenesis 38 .”
Ozmen, F., Ozmen, T. Y., Ors, A., Janghorban, M., Rames, M. J., Li, X., Doe, A. R., Behbod, F., Mills, G. B., & Mohammed, H. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00808-w · Cited by 24
Design of Nanoparticles in Cancer Therapy Based on Tumor Microenvironment Properties
Firouzabadi, B. M., Gigliobianco, M. R., Joseph, J. M., Censi, R., & Martino, P. D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122708 · Cited by 22
“Treg and myeloid-derived suppressor cells (MDSCs) [69,70].”
Wu, C. J., Duan, L., Li, H., Liu, X., Cai, T., Yang, Y., Yin, Y., Chang, W., Zhong, L., Zhang, L., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1303 · Cited by 21
“78 Through their release of paracrine factors (e.g. IL-10 and amphiregulin) and modulation of macrophage function, Tregs can indirectly influence angiogenesis beyond their VEGF-mediated effects.”
BackgroundSelf-citationEpigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy
Singh, V., Nandi, S., Ghosh, A., Adhikary, S., Mukherjee, S., Roy, S., & Das, C. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10167-w · Cited by 23
Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer
Jama, M., Tabana, Y., & Barakat, K. (2024) · European journal of medical research · doi:10.1186/s40001-024-01901-9 · Cited by 23
“They constitutively express CTLA-4, which inhibits CD4 + and CD8 + cytotoxic T cells in the TME [25, 55, 79].”
BackgroundThe role of metabolic reprogramming in immune escape of triple-negative breast cancer
Bao, R., Qu, H., Li, B., Cheng, K., Miao, Y., & Wang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424237 · Cited by 23
Strategies for Enhancing Vaccine-Induced CTL Antitumor Immune Responses
Yong, X., Xiao, Y., Luo, G., He, B., Lü, M., Hu, C.-J., Guo, H. Y., & Yang, S. (2012) · BioMed Research International · doi:10.1155/2012/605045 · Cited by 21
“M2-like macrophages secrete and release cytokines such as CCL17, CCL22, or CCL24, which recruit Treg cells to the local environment [57].”
BackgroundPanda, S., Padhiary, S. K., & Routray, S. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.06.008 · Cited by 20
Han, Y., Wang, X., Xia, K., & Su, T. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4990 · Cited by 28
“Specifically, hypoxia can induce immune cells and immune cytokines, impair the immune response against cancer (8), and further affect immunotherapy (9).”
BackgroundEngineering immunomodulatory hydrogels and cell-laden systems towards bone regeneration
Nadine, S., Correia, C. R., & Mano, J. F. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.213058 · Cited by 22
Dey, M., Chang, A. L., Wainwright, D. A., Ahmed, A. U., Han, Y., Balyasnikova, I. V., & Lesniak, M. S. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.10.012 · Cited by 21
“…be critical in recruiting Tregs to brain tumors, several other factors involving tumor-associated cellular hypoxia and tumorexpressed indoleamine 2,3-dioxygenase have also been shown to regulate Treg recruitment and/or expansion (Fang et al., 2003; Facciabene et al., 2011;Wainwright et al., 2012).”
BackgroundInfluentialWen, K., Yan, Y., Shi, J., Hu, L., Wang, W., Liao, H., Li, H., Zhu, Y., Mao, K., & Xiao, Z. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.809672 · Cited by 24
“Hypoxia promotes tumor cells to express a large amount of CCL28 receptors, which recruit Tregs into tumor tissues and interact with CCR10 on Tregs surface to exert immunosuppressive effect (Facciabene et al., 2011).”
BackgroundMendoza‐Reinoso, V., Schnepp, P. M., Baek, D. Y., Rubin, J. R., Schipani, E., Keller, E. T., McCauley, L. K., & Roca, H. (2022) · Cells · doi:10.3390/cells11233712 · Cited by 22
Metadata
- Authors
- Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., & Coukos, G.
- Affiliations
- University of Pennsylvania (US)
- University of British Columbia (CA)
- Corresponding author
- Coukos, George
- ORCID
- Venue
- Nature
- Published
- 2011-07
- Volume
- 475
- Issue
- 7355
- Pages
- 226-230
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142644858
- Cited by
- 1,376
- References
- 38
- Citations by year
- 2026: 54 · 2025: 90 · 2024: 112 · 2023: 113 · 2022: 151 · 2021: 152 · 2020: 119 · 2019: 105 · 2018: 77 · 2017: 85 · 2016: 74 · 2015: 55 · 2014: 55 · 2013: 69 · 2012: 50
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA116779, P01 CA 83638)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- tumor hypoxia, regulatory T cells, CCL28, chemokine recruitment, tumor angiogenesis, VEGF-A, tumor immune evasion, tumor growth, chemokines
- MeSH terms
- Animals, Female, Humans, Immune Tolerance, Mice, Inbred C57BL, Neovascularization, Pathologic, Ovarian Neoplasms, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Culture Media, Conditioned, Disease Progression, Chemokines, CC, Vascular Endothelial Growth Factor A, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, Receptors, CCR10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.